INVESTORS

SOLID SCIENCE - NEAR TERM  
GROWTH OPPORTUNITY

Gene therapy is one of the hottest growth areas in biotech with about  $10 Billion invested annually  over the last several years.

Cellastra is targeting unmet needs in Long COVID, Surgery & Burn Care. The Long COVID has been referred to as a $3.5 Trillion challenge (David Cutler, Harvard Economist).

 

VIRLEXA GENE VECTOR , nhaled once, may bind to the same  receptors as COVID and help block further infection. It may also  program the lung epithelium to produce  ensereptide, a natural peptide,  which may help mitigate root causes of tissue damage and scarring during the acute phase of the infection,

 

The vector may also be given as an intramuscular injection, 

which may enable production of  ensereptide for many months and provide system wide protection against Long COVID affecting multiple organs,

SCARLEXA Gene Therapy, applied in the wound area after surgery or burn injuries, switches on the production of natural anti-scarring peptides, which have already been found to be safe and effective in clinical studies to date.

Rather than trying to apply topical treatment for weeks or months, one treatment with SCARLEXA turns on the production of the peptide at the site of the injury for many weeks or months.

See Investor Contacts:

Investor.jpg

Welcome to

THE NEXT BIG THING

Cellastra Presentation on Long COVID 23 September, 2022

Cellastra Executive Summary Long COVID   12 September, 2022 

Learn about the $3.5 Trilliion Long COVID challenge 

https://abcn.ws/3KKdR9L



 



 

 

December 10, 2021